Dr. Li is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Providence Hwy
Boston Biomedical, Inc.
Norwood, MA 02062Phone+1 781-278-0846Fax+1 781-762-9863
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Gastroenterology, 2001 - 2004
- Brigham and Women's HospitalResidency, Internal Medicine, 1998 - 2001
- Harvard Medical SchoolClass of 1998
Publications & Presentations
PubMed
- 2 citationsRandomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.Manish A Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C Tebbutt
Clinical Cancer Research. 2022-07-14 - Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarc...Manish A Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C Tebbutt
Clinical cancer research : an official journal of the American Association for Cancer Research. 2022-05-26 - Synthetic Biology Medicine and Bacteria-Based Cancer Therapeutics.Jaehyung Lee, Andrew C. Keates, Chiang J. Li
Methods in Molecular Biology. 2021-01-01
Press Mentions
- The End of Toxic Chemo and RadiationDecember 23rd, 2019
- Boston Biomedical Presents Clinical Data on First-in-Class Cancer Stemness Inhibitor Napabucasin at 2017 ASCO GI SymposiumJanuary 21st, 2017
- Boston Biomedical Presents Clinical Data on First-in-Class Cancer Stemness Inhibitor Napabucasin at 2017 ASCO GI SymposiumJanuary 21st, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: